Predictive Oncology (US:POAI)2026-03-31 20:15Market Projections - The global compute market is projected to exceed $1 trillion by 2026, with a compound annual growth rate of approximately 9.9%[15]. - The AI compute market is expected to grow at rates exceeding 30% annually, reaching over $1 trillion by 2034[15]. - The global cloud computing market is projected to grow from approximately $1 trillion in 2026 to between $2.4 trillion and $3.3 trillion by 2030 to 2033, with a compound annual growth rate of about 16% to 20%[54]. - AI-related computing spending is expected to reach $2.52 trillion in 2026, marking a 44% year-over-year increase, driven by the demand for AI-optimized servers[54]. - Approximately $6.7 trillion is expected to be spent on data centers globally between 2025 and 2030, with approximately 65.7% being GPU-related[168]. Company Financials - For the year ended December 31, 2025, the Company incurred losses from continuing operations of $232,853,647, with an accumulated deficit of $413,521,474[196]. - Revenue for 2025 was $125,284, an increase of $40,472 compared to $84,812 in 2024, primarily due to the completion of a tumor-specific 3D model[201]. - The company recorded a loss on digital assets of $152,490,550 in 2025, with no such losses in 2024, primarily from changes in the fair value of ATH holdings[202]. - General and administrative expenses rose to $25,924,358 in 2025, an increase of $18,688,561 from $7,235,797 in 2024, mainly due to stock-based compensation and professional service fees[204]. - Net cash used in operating activities of continuing operations was $9,876,039 in 2025, a decrease from $10,103,084 in 2024, attributed to lower cash operating losses[211]. - Cash and cash equivalents increased by $10,179,028 to $10,790,850 as of December 31, 2025[210]. - Net cash used in investing activities of continuing operations was $32,616,819 in 2025, significantly higher than $9,510 in 2024, due to digital asset purchases[212]. - Total operating loss for 2025 was $(180,915,715), compared to $(10,303,930) in 2024, reflecting a significant increase in losses[201]. - Research and development expenses decreased slightly to $2,147,222 in 2025 from $2,241,461 in 2024, indicating stable investment in product development[205]. - Sales and marketing expenses decreased to $406,247 in 2025 from $833,199 in 2024, primarily due to the absence of staff-related expenses[206]. - Other expenses for 2025 totaled $(51,937,932), a significant increase from other income of $79,275 in 2024, mainly due to losses related to the fair value of derivatives[207]. Digital Asset Strategy - The company has adopted a digital asset treasury strategy focused on ATH, which may face challenges in implementation and profitability due to the need for specialized skills and infrastructure[76]. - The company’s treasury strategy aims to utilize proceeds from equity and debt financings to purchase and hold ATH, with a focus on staking the majority of ATH to earn yield[39]. - The company completed two private investment in public equity transactions (PIPEs) totaling approximately $343.5 million to support its digital asset treasury strategy[23]. - The Treasury Strategy is primarily dedicated to ATH, with a significant portion of the Company's balance sheet allocated to holding ATH[172]. - The company plans to continue acquiring additional ATH in the open market and earn yield on its ATH treasury holdings through staking[37]. - ATH's price has significantly declined from a high of $0.067072 on September 17, 2025, to $0.004919 on February 6, 2026, indicating high volatility and risk associated with concentrated holdings[78]. - The liquidity of ATH is limited, trading on a small number of exchanges, which could impair the company's ability to sell ATH at favorable prices during adverse market conditions[81]. - The company’s treasury strategy is concentrated in ATH, increasing exposure to macroeconomic risks and potential adverse impacts from broader cryptocurrency market declines[82]. - The Aethir network's performance is critical; disruptions could prevent transactions and negatively impact ATH's value[83]. - Regulatory changes and increased scrutiny from agencies like the SEC could adversely affect ATH's market price and the company's financial condition[86]. Operational Challenges - The average lead time for data center GPUs is currently between 36 to 52 weeks, indicating a significant supply-demand imbalance[15]. - The company maintains relationships with multiple GPU hardware suppliers to mitigate risks associated with supply constraints, particularly from NVIDIA Corporation[64][65]. - The company may face operational challenges and risks associated with acquisitions, including increased indebtedness and contingent purchase price obligations[145]. - The company’s shift towards an Aethir-focused strategy requires significant operational adjustments and exposes it to cybersecurity risks[77]. - Cybersecurity risks have not materially affected the company’s business strategy, results of operations, or financial condition to date[156]. - Geopolitical tensions, particularly between the U.S. and China, could disrupt GPU supply chains and limit the company's addressable market[93]. - Data centers are projected to account for over 10% of total U.S. energy consumption by 2030, which may lead to increased regulatory costs and operational limitations for the compute market[94]. Drug Discovery and Biobank - The company is exploring strategic alternatives for its legacy Drug Discovery Services business, which includes a proprietary biobank of over 150,000 tumor samples[20]. - The PEDAL platform utilizes a biobank of over 150,000 patient tumor samples to create AI-driven predictive models of tumor drug response, significantly enhancing the probability of clinical success and reducing time and costs in oncology drug discovery[41][42]. - The 3D tumor-specific models developed by the company provide drug response predictions with high correlation to clinical responses, enhancing pipeline prioritization for biopharma clients[46][49]. - The company’s unique access to a privately held biobank offers a competitive advantage in drug response prediction, creating barriers to entry for competitors[61]. - The integration of AI with extensive tumor data allows for actionable insights critical to new drug development and individual patient treatment strategies[62]. - The company aims to leverage the PEDAL platform to assist biopharma clients in prioritizing oncology portfolios and repurposing previously failed drug compounds[56]. - New oncology drug compounds typically take 10-12 years to gain approval, with an estimated 90-95% failure rate during clinical trials due to inability to meet therapeutic endpoints[60]. - The FDA Modernization Act 2.0 is anticipated to increase the use of non-animal testing methods, promoting more efficient and predictive models in drug development[57]. Compliance and Regulatory Issues - The company has faced compliance issues with Nasdaq regarding its stock price, having previously executed a 20-for-1 reverse stock split to regain compliance[115]. - The company has regained compliance with Nasdaq's Minimum Bid Price Requirement as of January 3, 2025, after trading above the minimum requirement[116]. - As of September 30, 2024, the company's stockholders' equity was $1,966,969, which is below the Nasdaq minimum requirement of $2.5 million[117]. - The company was notified on June 9, 2025, that it had not regained compliance with the Stockholders' Equity Requirement, leading to a potential delisting from Nasdaq[118]. - The company did not comply with the Minimum Bid Price Requirement, as the closing bid price was below $1.00 for 30 consecutive trading days[119]. - An oral hearing was held on July 17, 2025, where the company presented plans to regain compliance, including potential sales of common stock and a reverse stock split[120]. - Nasdaq granted an extension through December 8, 2025, for the company to demonstrate compliance with continued listing requirements[121]. - A Reverse Stock Split was completed on September 29, 2025, resulting in a significant increase in stock price and regaining compliance with the Minimum Bid Price Requirement[122]. - On December 2, 2025, Nasdaq confirmed that the company had regained compliance with the minimum stockholders' equity requirement[123]. - Regulatory changes could require the company to register as a money services business, leading to increased compliance costs and potential operational shutdowns[101]. - The regulatory landscape for digital assets is rapidly evolving, which may materially affect the Company's operations and financial performance[186].